Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 15/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 15/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067564 | 0.95 | DRD2 (0.43) | CARM1PRMT6DRD2DRD3USP2 | |
| SCHEMBL5067621 | 0.86 | CARM1 (0.41) | CARM1PRMT6DRD2HTR1ADRD4 | |
| SCHEMBL5069665 | 0.79 | CARM1 (0.44) | CARM1PRMT6 | |
| SCHEMBL5067039 | 0.79 | CARM1 (0.44) | CARM1PRMT6DRD2HTR1ADRD4 | |
| SCHEMBL5066896 | 0.77 | CARM1 (0.58) | CARM1 | |
| SCHEMBL5069685 | 0.77 | CARM1 (0.49) | CARM1 | |
| SCHEMBL5064263 | 0.76 | CARM1 (0.49) | CARM1LMNA | |
| SCHEMBL5066895 | 0.76 | CARM1 (0.48) | CARM1PRMT6 | |
| SCHEMBL5069644 | 0.76 | CARM1 (0.48) | CARM1 | |
| SCHEMBL5066866 | 0.74 | CARM1 (0.43) | CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | CARM1 1/4885PRMT6 5/4885DRD2 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.